Introduction: Research Studies

Improving What's Possible

As a University Medical Center, we have the privilege and duty to try to improve medical care, as well as to provide the best available care. We are very active in two primary types of research:

  • Clinical research — Clinical research is the study of disease in patients, often involving clinical trials (or studies). These studies involve human volunteers to help answer specific health questions. Carefully conducted clinical trials are the best way to find treatments that really work. All such studies are very carefully designed and regulated to make them as safe as possible. They are handled by our own professional research management team.
  • Basic science research — Basic science research is carried out in laboratories, studying mechanisms of disease and new medicines. Much of this research concerns the basic mechanisms of cancer, and is carried out in collaboration with scientists in the Hollings Cancer Center.

Participants involved in clinical research trials can play a more active role in their own health care, gain access to new research treatments before they are widely available, and help others by contributing to medical research.

Be sure to read our Patient Safety, Rights and Responsibilities and Frequently Asked Questions pages.

Those interested in even more information can contact the program manager, April Williams at williamsa@musc.edu or (843) 876-4303.

Biliary/Pancreatic Research Thrives at MUSC

New studies in sphincter of Oddi dysfunction

MUSC faculty continue to address important issues in biliary and pancreatic medicine. Joe Elmunzer and team have NIH funding to establish the best method to prevent pancreatitis after ERCP procedures. The SVI study is designed to establish whether medical intervention (Indomethacin) is as effective as the combination of Indomethacin and a pancreatic Stent. It is being carried out in 14 centers across USA and has already enrolled in excess of 600 subjects judged to be at increased risk of pancreatitis. Many of these subjects have post-cholecystectomy biliary pain, or unexplained idiopathic recurrent pancreatitis (IRAP), and are suspected to have "sphincter of Oddi dysfunction (SOD)".

The earlier NIH-funded EPISOD study, led by Peter Cotton, was an iconoclastic contribution to the field of gastroenterology. In addition to setting a new standard for sham-controlled trials in endoscopy, EPISOD established that patients diagnosed with SOD based on the presence of biliary- or pancreatic-type abdominal pain alone – previously called "SOD type III," fared no better after a sphincterotomy than a sham intervention (www.EPISOD.com). Given the substantial short- and long-term risks of ERCP, including post-ERCP pancreatitis, bleeding, perforation, and post-sphincterotomy re-stenosis (scarring), EPISOD has changed clinical practice: fewer patients are now offered ERCP for biliary- or pancreatic-type pain alone.

What remains controversial is the role of ERCP and sphincterotomy in two other groups of patients still classified as SOD: first, those who have biliary-type abdominal pain with a dilated bile duct or abnormal liver chemistries; second, those who have pancreatic-type abdominal pain with a dilated pancreatic duct, abnormal pancreas chemistries, or simply unexplained episodes of acute pancreatitis. Based on limited evidence, many patients are offered ERCP and sphincterotomy when the symptoms are severe enough to warrant the risks of the procedure. The SVI study includes many of those patients, but follows them for only a month after sphincterotomy to measure the incidence of post-ERCP pancreatitis.

RESPOnD logo

Greg Cote and team have received NIH funding to perform the RESPOnD (Results of ERCP in SPhincter of Oddi Dysfunction) study, which will follow patients who undergo ERCP for SOD for a full year. The goal is to establish the precise characteristics of patients who benefit, and of those who do not, to better inform future practice. This is important, not least because the treatment (ERCP and sphincterotomy) has substantial risks as detailed above. Patients with suspected SOD who are not in the SVI trial may also be enrolled in RESPOnD. In addition to studying the impact of ERCP on biliary- and pancreatic-type pain, RESPOnD will also evaluate the role of sphincterotomy in reducing the risk of recurrent idiopathic pancreatitis. The study will commence early in 2018 and enroll up to 400 patients. It will be by far the largest study of this problem, and should produce definitive results.

Details of these, and other ingoing studies, can be found at SCResearch.org or by contacting the project manager April Williams at (843) 876-4303.